

## granisetron 3.1mg / 24 hours transdermal patch (Sancuso®) (No: 895/13) ProStrakan Ltd

09 August 2013 (Issued 06 September 2013)

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**granisetron 3.1mg / 24 hours transdermal patch (Sancuso®)** is accepted for use within NHS Scotland.

**Indication under review:** in adults for the prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy, for a planned duration of 3 to 5 consecutive days, where oral anti-emetic administration is complicated by factors making swallowing difficult.

Granisetron 3.1mg / 24 hours transdermal patch is slightly more expensive than the oral formulation. It provides an alternative option in patients who have difficulty swallowing oral medication.

### **Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including **05 September 2013**.*

**Vice Chairman**  
**Scottish Medicines Consortium**